Please login to the form below
AZD3293
This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down
Latest news
-
Biogen rises on more positive data for Alzheimer's candidate
compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
-
Lilly taps AstraZeneca for another anti-amyloid drug
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
-
Lilly sinks as solanezumab fails again in Alzheimer's
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
-
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug
AMARANTH could be first treatment to target underlying mechanism. AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase II/III
-
Eisai and Biogen plan phase III trials for Alzheimer's drug
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
